A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
Latest Information Update: 10 Jun 2024
At a glance
- Drugs Simufilam (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Registrational; Therapeutic Use
- Acronyms RETHINK-1; RETHINK-ALZ
- Sponsors Cassava Sciences
- 10 May 2024 According to a Cassava Sciences media release, top-line data readout for our 52-week study (RETHINK-ALZ) is expected in year-end 2024.
- 25 Mar 2024 According to a Cassava Sciences media release, the company announced the completion of another interim patient safety review by an Independent Data and Safety Monitoring Board (DSMB). DSMB recommended that trial continue as planned, without modification.
- 07 Mar 2024 Baseline Characteristics of RETHINK and REFOCUS Phase 3 trials presented at the 2024 International Conference on Alzheimer's and Parkinson's Disease (AD/PD 2024).